Post-adjuvant chemotherapy in ctDNA-positive patients with resected colorectal cancer: a randomized phase 3 trial.

Name: Αlpha¹ Rigor Record — Post-adjuvant chemotherapy in ctDNA-positive patients with resected colorectal cancer: a randomized phase 3 trial.
Item: Post-adjuvant chemotherapy in ctDNA-positive patients with resected colorectal cancer: a randomized phase 3 trial.
Rating: 100
Author: Αlpha¹

Bando H, Watanabe J, Takahashi Y, Kotaka M, Matsuhashi N, Oki E, Komatsu Y, Shiozawa M, Hirata K, Miyamoto Y, Takahashi M, Yamazaki K, Manaka D, Kanazawa A, Liang YH, Yeh KH, Watsuji Y, Yamamoto Y, Fukui M, Sharma S, Aushev VN, Jurdi A, Rabinowitz M, Liu MC, Aleshin A, Takemasa I, Kotani D, Sato A, Misumi T, Nakamura Y, Shi Q, Taniguchi H, Yoshino T, Kato T

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 3.5★ (Adequate), 0 critical, 2 high issues for “Post-adjuvant chemotherapy in ctDNA-positive patients with resected colorectal cancer: a randomized phase 3 trial.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 15, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

3.5 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern−0.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Problems surfaced4 types

Numerical inconsistencies1

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Overstated conclusions3

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions only partially backed by the presented evidenceAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted and transparently reported randomized phase 3 trial. The paper demonstrates strong scientific premise, rigorous design, and comprehensive reporting across all eight dimensions, with only minor reporting gaps such as the unspecified randomization method and minor copyedit inconsistencies.

Both reviewers independently scored all eight dimensions and agreed on every status; no divergence required reconciliation. The study is an interventional clinical trial; non-applicable sub-criteria (e.g., animal housing, cell line authentication) were excluded. The statistics verification recomputed only a subset of reported tests (9 of many), so the paper's statistics should not be considered fully verified beyond those checks.

5 major claims checked against the paper's own evidence: 2 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Recomputed 9 tests: 9 consistent, 0 inconsistent; 6 recomputed directly from the reported test statistics, 3 via agent-written checks.

1 integrity concern flagged (0 high).

Reporting

Eight Dimensions8 pass

The introduction cites multiple prior trials (DYNAMIC-II, DYNAMIC-III, RECOURSE) and discusses their strengths and limitations, including the failure of DYNAMIC-III to show benefit and the rationale for a uniform intervention. The premise that early intervention upon molecular recurrence may improve outcomes is logically developed, and the study addresses limitations of prior work by using a consistent treatment and a post-adjuvant surveillance strategy.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a strong scientific premise by citing prior research on ctDNA-guided therapy and FTD/TPI efficacy, and clearly links the rationale to the study objectives.

Evidence

paraphrase[Introduction, paragraphs 3-5]

“Evidence supporting ctDNA-guided ACT decision-making for stage II colon cancer has emerged from the randomized DYNAMIC-II trial, which demonstrated non-inferior recurrence-free survival with reduced chemotherapy use compared to standard management. However, the randomized DYNAMIC-III trial failed to demonstrate improved outcomes with ctDNA-guided treatment escalation or deescalation for stage III colon cancer.”

paraphrase[Introduction, paragraph 5]

“In the RECOURSE phase 3 trial, FTD/TPI significantly improved OS in patients with refractory metastatic CRC who had progressed after standard chemotherapy regimens... (7.1 months versus 5.3 months with placebo; hazard ratio (HR) = 0.68, 95% CI: 0.58–0.81, P < 0.001).”

direct quote[Discussion, paragraph 2]

“By contrast, ALTAIR was designed to evaluate a uniform intervention—FTD/TPI—against placebo after completion of SoC treatment, allowing a clearer assessment of drug-specific efficacy in the MRD-positive setting.”